3.4.0.0 For Pa­tients Using Basal In­sulin and/‍or Oral Agents

The ev­i­dence is insufficient re­gard­ing when to pre­scribe SMBG and how often test­ing is need­ed for in­sulin-‍treat­ed pa­tients who do not use in­ten­sive in­sulin reg­i­mens, such as those with type 2 di­a­betes using basal in­sulin with or with­out oral agents. How­ev­er, for pa­tients using basal in­sulin, as­sessing fast­ing glu­cose with SMBG to in­form dose ad­justments to achieve blood glu­cose tar­gets re­sults in lower A1C (47,48).

In peo­ple with type 2 di­a­betes not using in­sulin, rou­tine glu­cose mon­i­tor­ing may be of lim­it­ed ad­di­tion­al clin­i­cal benefit. For some in­di­vid­u­als, glu­cose mon­i­tor­ing can pro­vide in­sight into the im­pact of diet, phys­i­cal ac­tiv­i­ty, and med­i­ca­tion man­agement on glu­cose lev­els. Glu­cose mon­i­tor­ing may also be use­ful in as­sessing hy­po­glycemia, glu­cose lev­els dur­ing intercur­rent ill­ness, or dis­crep­an­cies be­tween mea­sured A1C and glu­cose lev­els when there is con­cern an A1C re­sult may not be re­li­able in specific in­di­vid­u­als. How­ev­er, sev­er­al ran­dom­ized tri­als have called into ques­tion the clin­i­cal util­i­ty and cost-‍ef­fec­tive­ness of rou­tine SMBG in nonin­sulin-‍treat­ed pa­tients (49–52). In a year-‍long study of in­sulin-‍naive pa­tients with subop­ti­mal ini­tial glycemic con­trol, a group trained in struc­tured SMBG (a paper tool was used at least quar­ter­ly to col­lect and in­ter­pret seven-‍point SMBG profiles taken on 3 con­sec­u­tive days) re­duced their A1C by 0.3% more than the con­trol group (53). A trial of once-‍daily SMBG that in­cluded en­hanced pa­tient feed­back through mes­sag­ing found no clin­i­cally or sta­tis­ti­cal­ly sig­nif­i­cant change in A1C at 1 year (52). Meta-‍anal­y­ses have sug­gest­ed that SMBG can re­duce A1C by 0.25–0.3% at 6 months (54–56), but the ef­fect was at­ten­u­at­ed at 12 months in one anal­y­sis (54). Re­duc­tions in A1C were greater (-0.3%) in tri­als where struc­tured SMBG data were used to ad­just med­i­ca­tions but not significant with­out such struc­tured di­a­betes ther­a­py ad­justment (56). A key con­sid­er­a­tion is that per­form­ing SMBG alone does not lower blood glu­cose lev­els. To be use­ful, the in­for­ma­tion must be in­te­grat­ed into clin­i­cal and self-man­agement plans.